The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management
复制标题
DOI：
10.1517/14712590802643347
复制
发表时间：
2009-02-01
影响因子：
4.6
通讯作者：
Verschraegen, Claire
中科院分区：
文献类型：
--
作者：
Movva, Sujana;Verschraegen, Claire
背景：细胞毒性T淋巴细胞抗原4(CTLA-4)是T细胞抗肿瘤免疫反应的抑制性调节因子。Ipilimumab(MDX-010)是一种针对CTLA-4的单抗。目的：描述ipilimumab的基本作用机制，并讨论有关其安全性和有效性的现有数据。方法：使用PubMed数据库和美国临床肿瘤学会摘要数据库对包括摘要在内的临床试验数据进行综述。结论：用单抗抑制CTLA-4通常耐受性好，可作为多种癌症的治疗剂。临床上最重要的毒性与自身免疫事件有关，目前已有治疗这些影响的指南。初步结果表明，使用ipilimumab治疗会产生持久的反应。其药代动力学和药效学与传统化疗药物不同。目前正在进行毛皮黑色素瘤的第三阶段研究。
Background: Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T cell immune response against tumor cells. Ipilimumab (MDX-010) is a monoclonal antibody directed against CTLA-4. Objective: To describe the basic mechanism of ipilimumab and discuss data available to date with regards to its safety and efficacy profile. Methods: Data from clinical trials including abstracts were reviewed using the PubMed Database as well as the American Society of Clinical Oncology Abstract Database. Conclusions: CTLA-4 inhibition with a monoclonal antibody is usually well tolerated and has efficacy as a therapeutic agent in a variety of cancers. The most clinically important toxicities have been related to autoimmune events, and guidelines for treatment of these effects are now available. Preliminary results indicate that therapy with ipilimumab leads to durable responses. Pharmacokinetics and pharmacodynamics are different from those of traditional chemotherapy agents. Phase III studies are currently underway fur melanoma.